CoChat

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel

Open access
Kharaziha, Pedram, Chioureas, Dimitris, Rutishauser, Dorothea, Baltatzis, George, Lennartsson, Lena, Fonseca, Pedro, Azimi, Alireza, Hultenby, Kjell, Zubarev, Roman, Ullén, Anders, Yachnin, Jeffrey, Nilsson, Sten, Panaretakis, Theocharis · 2015 · Oncotarget
Cited by 149

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Pedram Kharaziha 1 , Dimitris Chioureas 1 , Dorothea Rutishauser 2, 3 , George Baltatzis 4 , Lena Lennartsson 1 , Pedro Fonseca 1 , Alireza Azimi 1 , Kjell Hultenby 5 , Roman Zubarev 2, 3 , Anders Ullén 1 , Jeffrey Yachnin 1 , Sten Nilsson 1 , Theocharis Panaretakis 1 1 Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden 2 Department of Medical Biochemistry and Biophysics, Karolinska Institutet and University Hospital, Stockholm, Sweden 3 Science for Life Laboratory, Stockholm, Sweden 4 Department of Medicine, School of Health Sciences, University of Athens, Athens, Greece 5 Department of Laboratory Medicine, Karolinska Institutet and University Hospital, Huddinge, Sweden Correspondence to: Theocharis Panaretakis, e-mail: theoharis.panaretakis@ki.se Keywords: Prostate cancer, exosomes, docetaxel, resistance, biomarkers Received: September 17, 2014 Accepted: January 27, 2015 Published: March 12, 2015 ABSTRACT Docetaxel is a cornerstone treatment for metastatic, castration resistant prostate cancer (CRPC) which remains a leading cause of cancer-related deaths, worldwide. The clinical usage of docetaxel has resulted in modest gains in survival, primarily due to the development of resistance. There are currently no clinical biomarkers available that predict whether a CRPC patient will respond or acquire resistance to this therapy. Comparative proteomics analysis of exosomes secreted from DU145 prostate cancer cells that are sensitive (DU145 Tax-Sen) or have acquired resistance (DU145 Tax-Res) to docetaxel, demonstrated significant differences in the amount of exosomes secreted and in their molecular composition. A panel of proteins was identified by proteomics to be differentially enriched in DU145 Tax-Res compared to DU145 Tax-Sen exosomes and was validated by western blotting. Importantly, we identified MDR-1, MDR-3, Endophilin-A2 and PABP4 that were enriched only in DU145 Tax-Res exosomes. We validated the presence of these proteins in the serum of a small cohort of patients. DU145 cells that have uptaken DU145 Tax-Res exosomes show properties of increased matrix degradation. In summary, exosomes derived from DU145 Tax-Res cells may be a valuable source of biomarkers for response to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3226

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Kharaziha, P., Chioureas, D., Rutishauser, D., Baltatzis, G., Lennartsson, L., Fonseca, P., Azimi, A., Hultenby, K., Zubarev, R., Ullén, A., Yachnin, J., Nilsson, S., & Panaretakis, T.
Venue
Oncotarget
Published
2015-03-12
Volume
6
Issue
25
Pages
21740-21754
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1902243229
Cited by
149
References
6
FWCI
6.56
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.